If MKS was sitting on your watchlist instead of in your portfolio, the recent move may feel like a missed shot. Investors who held MKS over the past year are up 106.3%, including dividends. That outcome now sits alongside fresh headlines about capacity expansions in Asia and AI driven semiconductor demand, but back on 7 October 2025 the live question was simpler. Could the shift toward chemistry and services as a larger share of sales really justify treating MKS as a structurally different business?
The move put MKS in the middle of this trade. Scan 91 AI infrastructure stocks for other companies exposed to it.
The Two Competing Stories Around MKS
The shares cost US$129 at the start of the period, and anyone looking at MKS had to decide which story about its future sounded more reasonable.
The bullish narrative set a Fair Value of US$160, effectively the price implied if strong chemistry and services demand and high switching costs supported what those analysts saw as durable expansion. Supporters leaned on AI, advanced packaging, renewables, and the Atotech acquisition to argue for broader, more diversified end markets.
The more cautious view anchored on a Fair Value of US$122, reflecting expectations built on 5.4% annual revenue growth assumptions and a future P/E of 24.0x. That side focused on leverage near 4x EBITDA, customer concentration, trade risks, and competition as reasons earnings could prove bumpier than the optimists hoped.
What The Results Changed For The MKS Story
MKS Inc. reported Q2 2026 revenue of US$1.25b and net income of US$175m, with net margin at 14.0% versus 6.4% in Q2 2025. That shift, along with growth in higher margin chemistry and services and Asian capacity projects, supported the optimistic case that the business could look more recurring and more profitable. Insider selling and valuation concerns pointed in the other direction, so the evidence cut both ways.
The live assumption back in October 2025 was that mix would tilt toward chemistry and services and lift profitability. When you test a similar claim elsewhere, track whether segment data and net margin move in the same direction over several reported periods, not just whether revenue is rising.
What MKS Buyers Are Being Asked To Believe Now
MKS now trades at US$273, after a gain of 106.3% over the past year, and the selected Narrative sees Fair Value above that level based on its own assumptions rather than proven outcomes.
That view leans on AI related demand, new Asian capacity and a larger recurring chemistry and service base. The key question for you is whether sustained AI driven orders can keep those new facilities running at levels that support the profitability mix the Narrative assumes.
"The deepening integration of advanced materials and chemistry equipment within MKS, supported by record chemistry equipment orders for several quarters and a rising share of AI related chemistry revenue, increases the opportunity for tools plus consumables cross selling and can support both revenue growth and higher gross margins."
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all
Find Your Own Contrarian Opportunity
The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?
- Company 1 - 46% below our estimate - uses a relationship-focused banker model to integrate a major merger while scaling specialty services.
- Company 2 - 26% below our estimate - advances late-stage kidney, gene-editing and endocrine therapies beyond an established treatment franchise.
- Company 3 - 35% below our estimate - leans on record digital-infrastructure backlogs tied to large data center and manufacturing projects.
That is three of the list. See the full list of 29 companies trading below our estimate →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com